Mirabegron has longer treatment persistence than antimuscarinics: Real‐world data from a Korean national cohort database

Aims To descriptively evaluate treatment persistence among adults who received mirabegron or antimuscarinics in South Korea. Methods This study involved a retrospective analysis of the Health Insurance Review and Assessment (HIRA) database. Patients (≥18 years) who had a new prescription for an over...

Full description

Saved in:

Bibliographic Details
Published in:	Neurourology and urodynamics Vol. 40; no. 8; pp. 1972 - 1980
Main Authors:	Lee, Kyu‐Sung, Park, Hyejeong, Kang, Danbee, Byun, Hye J., Foo, Chee Y., Hadi, Farid A., Kim, Soyoung, Cho, Juhee
Format:	Journal Article
Language:	English
Published:	Hoboken Wiley Subscription Services, Inc 01-11-2021
Subjects:	antimuscarinics Decision making Health care mirabegron overactive bladder Patients persistence South Korea South Korea
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Aims To descriptively evaluate treatment persistence among adults who received mirabegron or antimuscarinics in South Korea. Methods This study involved a retrospective analysis of the Health Insurance Review and Assessment (HIRA) database. Patients (≥18 years) who had a new prescription for an overactive bladder (OAB) target medication (mirabegron/antimuscarinic) within an 8‐month index period (July 1, 2015–February 29, 2016) were included. The date when the target (index) medication was dispensed was the index date. The 6‐month period before the index date was used to assess patient eligibility. A 12‐month post‐index period was used to assess medication persistence, which was defined as the time to discontinuation. Overall data were analyzed and the results were also stratified by age group (≤65, >65 years), sex, or prior OAB medication experience. Persistence rates were calculated after the 1st, 3rd, 6th, 9th, and 12th months. Results A data set of 52 722 cases was obtained (mirabegron: 11 424, antimuscarinics: 41 298). The mean age was 60.9 ± 16.1 years and the majority of the patients were female (30 862 [58.5%] patients). Median persistence was longer with mirabegron (51 days) versus antimuscarinics (25 days). The persistence rate with mirabegron was higher throughout the study compared with all the antimuscarinics (12‐month data: 13.5% and 4.9%, respectively). Longer treatment persistence was noted in older, male, and treatment‐experienced patients. Conclusion The results from the HIRA database showed that persistence was longer with mirabegron than with antimuscarinics in South Korea. This finding may help inform clinical decision‐making within the South Korean healthcare system.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0733-2467 1520-6777
DOI:	10.1002/nau.24776